Developer docs
API playgroundTry for free, no card

Search company profiles

Treace Medical Concepts

Full company profile

uuid00009o3

Namestring
Treace Medical Concepts
Legal namestring
Treace Medical Concepts, Inc.
Websiteurl
treace.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Treace Medical Concepts, Inc. is a medical technology company that develops and commercializes proprietary surgical systems for the correction of bunion and midfoot deformities, headquartered in Ponte Vedra Beach, Florida, and traded on NASDAQ under ticker TMCI since its April 2021 IPO. The company's portfolio is anchored by the patented Lapiplasty 3D Bunion Correction System, which uses a 'Correct Before You Cut' methodology to address all three planes of bunion deformity and secure the unstable first tarsometatarsal joint. Adjacent systems include Adductoplasty for midfoot correction, IntelliGuide patient-specific 3D-printed titanium cut guides, SpeedPlate/SpeedMTP/SpeedAkin rapid compression implants, SuperBite compression screws, and minimally invasive variants Nanoplasty (1.5 cm incision) and Percuplasty (percutaneous), supported by sterile-packed single-use instruments and biologic wedges.

The company sells exclusively to healthcare providers in the United States through a direct field sales organization covering defined geographic territories, with 3,337 active surgeons as of the most recent disclosure. Pricing is negotiated through group purchasing organization (GPO) contracts and institutional purchasing agreements with hospitals and ambulatory surgery centers; no public list pricing exists. Revenue is hardware sales of surgical implants and instruments, with FY2025 revenue of $212.7 million (up 2% YoY) at an 80.6% gross margin, though Q1 2026 revenue declined 10% YoY to $47.2 million and management has guided FY2026 to $202–212 million. The company operates at a net loss ($59.0M in FY2025; $18.0M in Q1 2026) and carries over 50 granted US patents protecting its core systems and instrumentation. In December 2025, Treace secured a $175 million debt facility from SLR Capital Partners to refinance and fund expansion.

Short descriptiontext

Treace Medical Concepts is a US medical device company that develops and sells proprietary surgical systems — led by the patented Lapiplasty 3D Bunion Correction System — for the correction of bunion and midfoot deformities, selling directly to a base of over 3,300 foot and ankle surgeons through hospitals and ambulatory surgery centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersPonte Vedra Beach, United States
HQ citystring
Ponte Vedra Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
foot and ankle surgery, bunion correction systems, midfoot deformity correction, orthopedic surgical implants, minimally invasive bunion surgery
Industry1 code
PRIMARYHLAHAEAA
Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Orthopedic Foot and Ankle Surgical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Surgical Implants and Instruments
TypeHardware Sales
Description

Treace Medical Concepts generates revenue through the sale of proprietary surgical implant systems and instruments for bunion and midfoot deformity correction. Revenue declined 10% year-over-year in Q1 2026 to $47.2 million, with full-year 2025 revenue of $212.7 million. The company operates with net losses, posting $(18.0) million net loss in Q1 2026 and $(59.0) million full-year 2025 net loss.

globenewswire.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure
Pricing details1 tier
1Medical device pricing through institutional contracts
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing determined through GPO contracts and institutional purchasing agreements with hospitals and ambulatory surgery centers.

globenewswire.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 13 records shown
1Lapiplasty
Description

3D Bunion Correction System - combination of instruments, implants, and surgical methods designed to surgically correct all three planes of bunion deformity

treace.com
+12 more records
Core offering1 text field

Treace Medical Concepts designs, manufactures, and sells proprietary surgical implant systems and instruments for the correction of bunion and midfoot deformities. Its flagship Lapiplasty 3D Bunion Correction System combines patented instruments, implants, and methods to address all three planes of bunion deformity, complemented by minimally invasive systems (Nanoplasty, Percuplasty, Micro-Lapiplasty), compression implants (SpeedPlate, SpeedMTP, SpeedAkin), patient-specific cut guides (IntelliGuide), and sterile single-use instruments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 0.8% radiographic recurrence rate at 48 months (HVA > 20 degrees)
+6 more records
Product overview1 text field

Treace Medical Concepts is a medical technology company offering a comprehensive portfolio of surgical systems for bunion and midfoot deformity correction. The core offerings include the Lapiplasty 3D Bunion Correction System (the foundational patented system addressing triplanar bunion correction), the Adductoplasty Midfoot Correction System, and two minimally invasive options: the Nanoplasty 3D MIS System (1.5cm incision) and Percuplasty Percutaneous System. These are complemented by rapid compression implant platforms (SpeedPlate, SpeedMTP, SpeedAkin) and the SuperBite Compression Screw System. Add-on modules include IntelliGuide Patient-Specific cut guides and sterile-packed single-use instruments. The portfolio addresses the full spectrum of bunion correction procedures from open to minimally invasive approaches.

Product and service16 records
1Lapiplasty 3D Bunion Correction System
CategoryBunion Correction System
Description

Combination of instruments, implants, and surgical methods designed to surgically correct all three planes of bunion deformity and secure the unstable joint, addressing the root cause of bunions for foot and ankle surgeons.

2Adductoplasty Midfoot Correction System
CategoryMidfoot Correction System
Description

Designed for reproducible surgical correction of midfoot deformities including adductus deformity and osteoarthritis using controlled planning, cutting, compression, and fixation.

3Nanoplasty 3D MIS Bunion Correction System
CategoryMinimally Invasive Bunion Correction
Description

Minimally invasive 3D bunion correction through a hidden 1.5 cm incision with predictability at every step, eliminating the steep learning curve of traditional MIS techniques.

4Percuplasty Percutaneous 3D Bunion Correction System
CategoryMinimally Invasive Bunion Correction
Description

Percutaneous approach to 3D bunion correction providing control and efficiency at every step with an ultra-low-profile jig for optimal visualization.

5SpeedMTP Rapid Compression Implant
CategoryCompression Implant
Description

Delivers speed and dynamic compression of a staple with the stability and strength of a titanium locking plate for first MTP fusion procedures, featuring an ultra-low-profile 1.3mm design.

6SpeedPlate Rapid Compression Implant
CategoryCompression Implant
Description

Market-leading rapid compression implant offering continuous dynamic compression across fusion sites with anatomic designs, manufactured from titanium alloy without nickel.

7SpeedAkin Anatomic Compression Implant
CategoryCompression Implant
Description

Unique anatomic contoured design that delivers flush dynamic compression through an efficient simple workflow for hallux (Akin) procedures.

8IntelliGuide Patient-Specific 3D Cut Guides
CategoryPatient-Specific Instrumentation
Description

First patented patient-specific 3D printed titanium cut guides for personalized 3D bunion and midfoot correction, customized to each patient's unique anatomy.

9SuperBite Compression Screw System
CategoryCompression Screw System
Description

Fully threaded compression screws powered by continuously variable thread pitch and optimized head design for advanced compression and stability in foot and ankle surgeries.

10Micro-Lapiplasty Minimally Invasive System
CategoryMinimally Invasive Bunion Correction
Description

Delivers the triplanar correction of Lapiplasty through a 2 cm incision using SpeedPlate technology, maximizing cosmesis without compromising correction.

11Mini-Adductoplasty Minimally Invasive Midfoot Correction
CategoryMinimally Invasive Midfoot Correction
Description

Novel cut guide allows for the same reliable correction of midfoot deformities as Adductoplasty through a 4 cm incision.

12Sterile-Packed Single-Use Instruments
CategorySurgical Instruments
Description

Sterile-packed, single-use instruments including LapiTome, RazorTome, FastGrafter, SpeedRelease, GreatRelease, TriTome, FeatherRasp, and Akinator for foot and ankle surgical procedures.

13Hammertoe PEEK Fixation System
CategoryFixation System
Description

Guided PEEK solution for hammertoe, claw toe, and mallet toe procedures.

14Biologics and Wedges
CategoryBiologics and Bone Grafts
Description

Treace Allograft Wedges engineered for strength and correction, and CortiFuse flowable cortical fibers for maximizing healing potential in foot and ankle procedures.

15HyperPlate XM Dynamic Compression Locking Implant System
CategoryCompression Implant
Description

Dynamic compression locking implant system with anatomic design for midfoot and hindfoot fusion procedures.

16SpeedTMT Rapid Compression Implant
CategoryCompression Implant
Description

Rapid compression implant combining staple speed with titanium locking plate stability for foot and ankle fusion procedures.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

CONMED offers orthopedic and general surgery devices including foot and ankle fixation products, representing a partial overlap with Treace's surgical implant and instrument portfolio.

TypeBroad incumbent
Description

Stryker is a diversified orthopedic medical device incumbent with broad surgical implant and instrument portfolios across multiple specialties, including foot and ankle through its Wright Medical acquisition, providing overlapping capabilities to Treace's portfolio.

TypeBroad incumbent
Description

DePuy Synthes is a global orthopedic trauma and reconstruction incumbent offering plates, screws, and surgical instruments applicable to foot and ankle surgery, representing a broader competitive presence than Treace's specialized portfolio.

TypeBroad incumbent
Description

Integra LifeSciences provides orthopedic fixation implants and instruments for extremities, including foot and ankle surgery, competing with Treace in plates, screws, and specialty surgical systems.

5Paragon 28
TypeDirect peer
Description

Paragon 28 is a pure-play foot and ankle orthopedic medical device company offering a broad portfolio of surgical implants and instruments for foot and ankle reconstruction, making it the closest direct competitor to Treace's bunion and midfoot correction franchise.

TypeBroad incumbent
Description

Zimmer Biomet is a major orthopedic medical device company with broad joint reconstruction, trauma, and surgical implant offerings that overlap with Treace's plates, screws, and fixation products for foot and ankle surgery.

TypeEmerging player
Description

Vilex is a smaller foot and ankle focused orthopedic device company offering bunion correction and fixation products that compete in adjacent niches to Treace's Lapiplasty system.

TypeDirect peer
Description

Arthrex is a global leader in orthopedic surgical devices with a dedicated foot and ankle product line that competes directly with Treace's Lapiplasty, Adductoplasty, and minimally invasive bunion correction systems.

TypeBroad incumbent
Description

Smith+Nephew is a global medical device incumbent with an orthopedic portfolio that includes foot and ankle reconstruction products, competing broadly with Treace in the surgical implant and instrument space.

TypeDirect peer
Description

Wright Medical, now part of Stryker, has historically been a leading foot and ankle specialist with bunion correction and midfoot reconstruction implants that overlap with Treace's core Lapiplasty offering.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Treace Medical Concepts

Orthopedic Foot and Ankle Surgical Devicestreace.com

Treace Medical Concepts is a US medical device company that develops and sells proprietary surgical systems — led by the patented Lapiplasty 3D Bunion Correction System — for the correction of bunion and midfoot deformities, selling directly to a base of over 3,300 foot and ankle surgeons through hospitals and ambulatory surgery centers.

What Treace Medical Concepts does

Treace Medical Concepts, Inc. is a medical technology company that develops and commercializes proprietary surgical systems for the correction of bunion and midfoot deformities, headquartered in Ponte Vedra Beach, Florida, and traded on NASDAQ under ticker TMCI since its April 2021 IPO. The company's portfolio is anchored by the patented Lapiplasty 3D Bunion Correction System, which uses a 'Correct Before You Cut' methodology to address all three planes of bunion deformity and secure the unstable first tarsometatarsal joint. Adjacent systems include Adductoplasty for midfoot correction, IntelliGuide patient-specific 3D-printed titanium cut guides, SpeedPlate/SpeedMTP/SpeedAkin rapid compression implants, SuperBite compression screws, and minimally invasive variants Nanoplasty (1.5 cm incision) and Percuplasty (percutaneous), supported by sterile-packed single-use instruments and biologic wedges.

The company sells exclusively to healthcare providers in the United States through a direct field sales organization covering defined geographic territories, with 3,337 active surgeons as of the most recent disclosure. Pricing is negotiated through group purchasing organization (GPO) contracts and institutional purchasing agreements with hospitals and ambulatory surgery centers; no public list pricing exists. Revenue is hardware sales of surgical implants and instruments, with FY2025 revenue of $212.7 million (up 2% YoY) at an 80.6% gross margin, though Q1 2026 revenue declined 10% YoY to $47.2 million and management has guided FY2026 to $202–212 million. The company operates at a net loss ($59.0M in FY2025; $18.0M in Q1 2026) and carries over 50 granted US patents protecting its core systems and instrumentation. In December 2025, Treace secured a $175 million debt facility from SLR Capital Partners to refinance and fund expansion.

Treace Medical Concepts firmographics

Firmographics
Name
Treace Medical Concepts
Legal name
Treace Medical Concepts, Inc.
Website
https://treace.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
251–500 employees
Short description
Treace Medical Concepts is a US medical device company that develops and sells proprietary surgical systems — led by the patented Lapiplasty 3D Bunion Correction System — for the correction of bunion and midfoot deformities, selling directly to a base of over 3,300 foot and ankle surgeons through hospitals and ambulatory surgery centers.
Ownership category
akta.pro rank

Treace Medical Concepts industry classification

Industry
Product category
Orthopedic Foot and Ankle Surgical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAA
Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Foot and ankle surgery
  • Bunion correction systems
  • Midfoot deformity correction
  • Orthopedic surgical implants
  • Minimally invasive bunion surgery

Where Treace Medical Concepts is headquartered

Location

Headquarters

HQ city
Ponte Vedra Beach
HQ country
United States
HQ region
North America

Offices6 records

Markets served

Treace Medical Concepts business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

  1. Surgical Implants and Instruments: Treace Medical Concepts generates revenue through the sale of proprietary surgical implant systems and instruments for bunion and midfoot deformity correction. Revenue declined 10% year-over-year in Q1 2026 to $47.2 million, with full-year 2025 revenue of $212.7 million. The company operates with net losses, posting $(18.0) million net loss in Q1 2026 and $(59.0) million full-year 2025 net loss.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goMedical device pricing through institutional contracts

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Treace Medical Concepts product offering

Product offering

Core offering

Treace Medical Concepts designs, manufactures, and sells proprietary surgical implant systems and instruments for the correction of bunion and midfoot deformities. Its flagship Lapiplasty 3D Bunion Correction System combines patented instruments, implants, and methods to address all three planes of bunion deformity, complemented by minimally invasive systems (Nanoplasty, Percuplasty, Micro-Lapiplasty), compression implants (SpeedPlate, SpeedMTP, SpeedAkin), patient-specific cut guides (IntelliGuide), and sterile single-use instruments.

Product overview

Treace Medical Concepts is a medical technology company offering a comprehensive portfolio of surgical systems for bunion and midfoot deformity correction. The core offerings include the Lapiplasty 3D Bunion Correction System (the foundational patented system addressing triplanar bunion correction), the Adductoplasty Midfoot Correction System, and two minimally invasive options: the Nanoplasty 3D MIS System (1.5cm incision) and Percuplasty Percutaneous System. These are complemented by rapid compression implant platforms (SpeedPlate, SpeedMTP, SpeedAkin) and the SuperBite Compression Screw System. Add-on modules include IntelliGuide Patient-Specific cut guides and sterile-packed single-use instruments. The portfolio addresses the full spectrum of bunion correction procedures from open to minimally invasive approaches.

Differentiator

Problem solved

Functional benefit

Brands

  • Lapiplasty: 3D Bunion Correction System - combination of instruments, implants, and surgical methods designed to surgically correct all three planes of bunion deformity
  • Adductoplasty
  • SpeedMTP
  • Nanoplasty
  • Percuplasty
  • SpeedPlate
  • IntelliGuide
  • SuperBite
  • SpeedAkin
  • Micro-Lapiplasty
  • Mini-Adductoplasty
  • HyperPlate XM
  • SpeedTMT

Products and services

  • Lapiplasty 3D Bunion Correction System Combination of instruments, implants, and surgical methods designed to surgically correct all three planes of bunion deformity and secure the unstable joint, addressing the root cause of bunions for foot and ankle surgeons.
  • Adductoplasty Midfoot Correction System Designed for reproducible surgical correction of midfoot deformities including adductus deformity and osteoarthritis using controlled planning, cutting, compression, and fixation.
  • Nanoplasty 3D MIS Bunion Correction System Minimally invasive 3D bunion correction through a hidden 1.5 cm incision with predictability at every step, eliminating the steep learning curve of traditional MIS techniques.
  • Percuplasty Percutaneous 3D Bunion Correction System Percutaneous approach to 3D bunion correction providing control and efficiency at every step with an ultra-low-profile jig for optimal visualization.
  • SpeedMTP Rapid Compression Implant Delivers speed and dynamic compression of a staple with the stability and strength of a titanium locking plate for first MTP fusion procedures, featuring an ultra-low-profile 1.3mm design.
  • SpeedPlate Rapid Compression Implant Market-leading rapid compression implant offering continuous dynamic compression across fusion sites with anatomic designs, manufactured from titanium alloy without nickel.
  • SpeedAkin Anatomic Compression Implant Unique anatomic contoured design that delivers flush dynamic compression through an efficient simple workflow for hallux (Akin) procedures.
  • IntelliGuide Patient-Specific 3D Cut Guides First patented patient-specific 3D printed titanium cut guides for personalized 3D bunion and midfoot correction, customized to each patient's unique anatomy.
  • SuperBite Compression Screw System Fully threaded compression screws powered by continuously variable thread pitch and optimized head design for advanced compression and stability in foot and ankle surgeries.
  • Micro-Lapiplasty Minimally Invasive System Delivers the triplanar correction of Lapiplasty through a 2 cm incision using SpeedPlate technology, maximizing cosmesis without compromising correction.
  • Mini-Adductoplasty Minimally Invasive Midfoot Correction Novel cut guide allows for the same reliable correction of midfoot deformities as Adductoplasty through a 4 cm incision.
  • Sterile-Packed Single-Use Instruments Sterile-packed, single-use instruments including LapiTome, RazorTome, FastGrafter, SpeedRelease, GreatRelease, TriTome, FeatherRasp, and Akinator for foot and ankle surgical procedures.
  • Hammertoe PEEK Fixation System Guided PEEK solution for hammertoe, claw toe, and mallet toe procedures.
  • Biologics and Wedges Treace Allograft Wedges engineered for strength and correction, and CortiFuse flowable cortical fibers for maximizing healing potential in foot and ankle procedures.
  • HyperPlate XM Dynamic Compression Locking Implant System Dynamic compression locking implant system with anatomic design for midfoot and hindfoot fusion procedures.
  • SpeedTMT Rapid Compression Implant Rapid compression implant combining staple speed with titanium locking plate stability for foot and ankle fusion procedures.

Quantifiable outcome

  • 0.8% radiographic recurrence rate at 48 months (HVA > 20 degrees)
  • +6 more outcomes

Companies that use Treace Medical Concepts

Customer profile

Named customers9 records

Segments2 records

Ideal customer profiles2 records

Treace Medical Concepts technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Treace Medical Concepts partnerships and signals

Strategic signal

Scale indicators12 records

Recent moves7 records

Expansion highlights4 records

Treace Medical Concepts competitors and assessment

Company assessment

Emerging players

  • CONMED: CONMED offers orthopedic and general surgery devices including foot and ankle fixation products, representing a partial overlap with Treace's surgical implant and instrument portfolio.
  • Vilex: Vilex is a smaller foot and ankle focused orthopedic device company offering bunion correction and fixation products that compete in adjacent niches to Treace's Lapiplasty system.

Broad incumbents

  • Stryker: Stryker is a diversified orthopedic medical device incumbent with broad surgical implant and instrument portfolios across multiple specialties, including foot and ankle through its Wright Medical acquisition, providing overlapping capabilities to Treace's portfolio.
  • DePuy Synthes (Johnson & Johnson MedTech): DePuy Synthes is a global orthopedic trauma and reconstruction incumbent offering plates, screws, and surgical instruments applicable to foot and ankle surgery, representing a broader competitive presence than Treace's specialized portfolio.
  • Integra LifeSciences: Integra LifeSciences provides orthopedic fixation implants and instruments for extremities, including foot and ankle surgery, competing with Treace in plates, screws, and specialty surgical systems.
  • Zimmer Biomet: Zimmer Biomet is a major orthopedic medical device company with broad joint reconstruction, trauma, and surgical implant offerings that overlap with Treace's plates, screws, and fixation products for foot and ankle surgery.
  • Smith+Nephew: Smith+Nephew is a global medical device incumbent with an orthopedic portfolio that includes foot and ankle reconstruction products, competing broadly with Treace in the surgical implant and instrument space.

Direct peers

  • Paragon 28: Paragon 28 is a pure-play foot and ankle orthopedic medical device company offering a broad portfolio of surgical implants and instruments for foot and ankle reconstruction, making it the closest direct competitor to Treace's bunion and midfoot correction franchise.
  • Arthrex: Arthrex is a global leader in orthopedic surgical devices with a dedicated foot and ankle product line that competes directly with Treace's Lapiplasty, Adductoplasty, and minimally invasive bunion correction systems.
  • Wright Medical (Stryker Foot & Ankle): Wright Medical, now part of Stryker, has historically been a leading foot and ankle specialist with bunion correction and midfoot reconstruction implants that overlap with Treace's core Lapiplasty offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Treace Medical Concepts social profiles

Digital presence

Treace Medical Concepts compliance and trust

Trust signal

Compliance1 record

Treace Medical Concepts financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Treace Medical Concepts leadership team

Management profile

Number of profiles

Profiles20 records

Treace Medical Concepts funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Treace Medical Concepts M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Treace Medical Concepts

What does Treace Medical Concepts do?

Treace Medical Concepts designs, manufactures, and sells proprietary surgical implant systems and instruments for the correction of bunion and midfoot deformities. Its flagship Lapiplasty 3D Bunion Correction System combines patented instruments, implants, and methods to address all three planes of bunion deformity, complemented by minimally invasive systems (Nanoplasty, Percuplasty, Micro-Lapiplasty), compression implants (SpeedPlate, SpeedMTP, SpeedAkin), patient-specific cut guides (IntelliGuide), and sterile single-use instruments.

Is Treace Medical Concepts a public or private company?

Treace Medical Concepts is a public company. It is classified as public and is currently operating.

When was Treace Medical Concepts founded?

Treace Medical Concepts was founded in 2014. It employs 251 to 500 people.

Where is Treace Medical Concepts based?

Treace Medical Concepts is headquartered in Ponte Vedra Beach, United States, in the North America region.

How does Treace Medical Concepts make money?

One revenue line is on record: surgical Implants and Instruments.

Who are Treace Medical Concepts's main competitors?

Emerging players on record are CONMED and Vilex. Broad incumbents are Stryker, DePuy Synthes (Johnson & Johnson MedTech), Integra LifeSciences, Zimmer Biomet and Smith+Nephew. Direct peers are Paragon 28, Arthrex and Wright Medical (Stryker Foot & Ankle).

Does Treace Medical Concepts have an API?

No public API is recorded for Treace Medical Concepts.

What industry is Treace Medical Concepts in?

Treace Medical Concepts's product category is Orthopedic Foot and Ankle Surgical Devices. Its primary akta.pro industry code is HLAHAEAA, Orthopedic Joint Reconstruction Implants (Hip/Knee/Shoulder/Elbow/Ankle). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldTreace Medical Concepts, Inc. (NASDAQ:TMCI) Stock Has Average Price Target of $6.17 According to AnalystsTreace Medical Concepts shares have an average analyst price target of $6.17 with a mixed Hold rating. CEO John Treace bought 11,000 shares at $4.34, and the company reported Q3 EPS of -$0.19, beating estimates. Analysts forecast a -0.80 EPS for the current year.American Banking and Market NewsTreace Medical Concepts, Inc. (NASDAQ:TMCI) Stock Rated “Hold” by Wall Street BrokeragesTreace Medical Concepts received an average 'Hold' rating from five analysts, with a 1-year price objective of $6.17. CEO John Treace bought 11,000 shares at $4.34, and the company reported Q4 EPS of -$0.19, beating the -$0.25 consensus. Analysts expect -0.80 EPS for the current fiscal year.MarketScreenerTreace Medical Concepts Shares Rise After Stifel UpgradeStifel upgraded Treace Medical Concepts to Buy from Hold, setting a price target of $6.50. The stock rose 18.49% on the day, and the company's shares are trading at $4.775.American Banking and Market NewsNeuroOne Medical Technologies (NASDAQ:NMTC) & Treace Medical Concepts (NASDAQ:TMCI) Critical ReviewNeuroOne Medical Technologies and Treace Medical Concepts are compared on profitability, valuation, and analyst ratings. NeuroOne has a higher consensus target price ($7.33 vs $5.00) and a stronger rating, while Treace beats on nine of fourteen factors. NeuroOne's beta is 0.95, lower than Treace's 1.59.Seeking AlphaTreace outlines $206M-$210M 2026 revenue range while targeting $700M TAM expansion (NASDAQ:TMCI)Treace Medical Concepts reported Q3 2026 revenue of $48.3 million, down 4% year-over-year, and narrowed its full-year 2026 revenue guidance to $206 million to $210 million. The company expects a return to growth in Q4 and anticipates a $700 million expansion of its total addressable market from new 2026 product launches.BenzingaTreace Medical Concepts Q3 2026 Earnings Call Transcript - Treace Medical Concepts (NASDAQ:TMCI)Treace Medical Concepts reported Q3 2026 revenue of $48.3 million, down 4% year-over-year, and narrowed its full-year 2026 revenue guidance to $206-210 million. The company expects Q4 growth from double-digit case volume and new product launches, including Superbite, Hyperplate, and Tailorplasty.ChartmillTreace Medical Concepts (NASDAQ:TMCI) Q3 Loss Narrows as Revenue Holds In LineTreace Medical Concepts reported Q3 2026 revenue of $48.3 million, slightly below consensus, but a net loss of $12.6 million was 27% narrower than expected. The company tightened full-year revenue guidance to $206–210 million and improved adjusted EBITDA guidance, with premarket shares rising 4.2%.YahooTreace Medical Concepts: Q3 Earnings SnapshotTreace Medical Concepts reported a third-quarter loss of $12.6 million, or 19 cents per share. The company posted revenue of $48.3 million for the period.TradingViewTreace Medical Concepts Reports $48.3 Million Revenue and Lower Q3 LossTreace Medical Concepts reported Q3 2026 revenue of $48.3 million, down 4% year over year, and a net loss of $12.6 million. Gross margin was 79.5% and Adjusted EBITDA was $0.3 million. The company updated its full-year revenue outlook to $206–210 million and expects a full-year Adjusted EBITDA loss of $1–2 million.MarketBeatTreace Medical Concepts (TMCI) Expected to Post Quarterly Earnings on FridayTreace Medical Concepts is expected to report Q3 2026 earnings on Friday, November 6th, with analysts projecting a loss of $0.26 per share and revenue of $47.80 million. The company's last quarterly EPS was -$0.24, beating the -$0.30 consensus, and revenue of $45.38 million exceeded expectations. CEO John Treace purchased 11,000 shares at $4.34 each.